Fusion Pharmaceuticals Inc. (FUSN) |
|
5.055 0.095 (1.92%)
|
06-09 14:37 |
|
Open: |
4.99 |
Pre. Close: |
4.96 |
|
High:
|
5.139 |
Low:
|
4.9601 |
|
Volume:
|
15,658 |
Market Cap:
|
345(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 2:15:04 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 6.57 One year: 7.68 |
| Support: |
Support1: 4.63 Support2: 4.01 |
| Resistance: |
Resistance1: 5.63 Resistance2: 6.57 |
| Pivot: |
4.71 |
| Moving Average: |
MA(5): 5.15 MA(20): 4.66
MA(100): 4.11 MA(250): 3.21 |
| MACD: |
MACD(12,26): 0.2  Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 61.9 %D(3): 69.5 |
| RSI: |
RSI(14): 58.9 |
| 52-week: |
High: 5.63 Low: 1.98 |
| Average Vol(K): |
3-Month: 71 (K) 10-Days: 90 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FUSN ] has closed below upper band by 35.6%. Bollinger Bands are 49.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.25 - 5.29 |
5.29 - 5.32 |
|
Low:
|
4.88 - 4.92 |
4.92 - 4.95 |
|
Close:
|
4.93 - 4.99 |
4.99 - 5.03 |
|
Company Description |
|
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada. |
Headline News |
Wed, 07 Jun 2023
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Wed, 31 May 2023
Fusion Pharmaceuticals to Present at the Jefferies Healthcare Conference - Yahoo Finance
Thu, 11 May 2023
Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates - Yahoo Finance
Tue, 09 May 2023
Fusion Pharmaceuticals to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day - Yahoo Finance
Thu, 20 Apr 2023
Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference - Yahoo Finance
Fri, 14 Apr 2023
Fusion Pharma: Targeted Radiopharmaceutical Therapy Developer ... - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
64 (M) |
|
% Held by Insiders
|
4.662e+007 (%) |
|
% Held by Institutions
|
5.9 (%) |
|
Shares Short
|
327 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-9.139e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-10 |
|
Return on Assets (ttm)
|
217.2 |
|
Return on Equity (ttm)
|
-23 |
|
Qtrly Rev. Growth
|
904000 |
|
Gross Profit (p.s.)
|
-0.9 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-2.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-84 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.78 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
272870 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
